Stockscreener 앱 받기
0.8875
2.05%
0.0178
시간 외 거래:
.91
0.0225
+2.54%
전일 마감가:
$0.8697
열려 있는:
$0.8521
하루 거래량:
115.46K
Relative Volume:
0.60
시가총액:
$64.37M
수익:
$8.23M
순이익/손실:
$-32.49M
주가수익비율:
-1.6745
EPS:
-0.53
순현금흐름:
$-19.91M
1주 성능:
+6.54%
1개월 성능:
+3.08%
6개월 성능:
-17.06%
1년 성능:
-32.25%
1일 변동 폭
$0.8401
$0.8999
1주일 범위
$0.821
$0.9137
52주 변동 폭
$0.7001
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
명칭
Clearside Biomedical Inc
전화
678-270-3631
주소
900 NORTH POINT PARKWAY, ALPHARETTA, GA
CLSD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.8875 | 64.37M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-21 | 개시 | Chardan Capital Markets | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2021-12-15 | 재개 | Wedbush | Outperform |
| 2021-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-05-13 | 개시 | ROTH Capital | Buy |
| 2019-08-09 | 다운그레이드 | Needham | Buy → Hold |
| 2018-11-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2018-11-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2018-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-06 | 재확인 | Needham | Buy |
| 2017-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2017-02-24 | 개시 | JP Morgan | Overweight |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-10-24 | 재확인 | Stifel | Buy |
모두보기
Clearside Biomedical Inc 주식(CLSD)의 최신 뉴스
Geode Capital Management LLC Has $726,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical to Participate in a Fireside Chat at the Ci - GuruFocus
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - GlobeNewswire
Clearside Biomedical Showcases Revolutionary Eye Treatment Platform at Major Healthcare Conference - Stock Titan
Clearside Biomedical (NASDAQ:CLSD) Raised to “Hold” at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
JMP maintains $5 price target on Clearside Biomedical stock By Investing.com - Investing.com Canada
Form DEFA14A Clearside Biomedical, - StreetInsider
CLSD Stock Sees Surge of Approximately 14.80% in Last Five Days - knoxdaily.com
Clearside Biomedical’s (CLSD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Clearside Biomedical stock hits 52-week low at $0.77 - Investing.com
Clearside Biomedical at Needham Conference: Strategic Developments in Retinal Therapies - Investing.com Canada
HC Wainwright Analysts Lift Earnings Estimates for CLSD - Defense World
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - The Manila Times
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical Inc (CLSD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Clearside Biomedical Inc 주식 (CLSD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Nov 01 '24 |
Buy |
1.00 |
36,500 |
36,500 |
100,000 |
| Chong Ngai Hang Victor | Chief Medical Officer |
Jun 24 '24 |
Buy |
1.06 |
23,500 |
24,910 |
63,500 |
| YERXA BENJAMIN R | Director |
May 15 '24 |
Buy |
1.31 |
7,813 |
10,235 |
17,957 |
0.39%
3.66%
자본화:
|
볼륨(24시간):